Overview

Arikayce liposomal is an antibiotic for treating adults with a lung infection caused by Mycobacterium avium complex (MAC), a group of bacteria commonly found in the environment, such as in soil and water. It is used in patients with limited treatment options who do not have cystic fibrosis.

Lung infection caused by MAC is rare, and Arikayce liposomal was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 April 2014.

Arikayce liposomal contains the active substance amikacin.

Amikacin is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that bacteria need to build their cell walls, thereby damaging the bacteria and eventually killing them. In this medicine, amikacin is contained in tiny fat particles known as liposomes, which allows the medicine to remain in the lung for longer.

Amikacin is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that bacteria need to build their cell walls, thereby damaging the bacteria and eventually killing them. In this medicine, amikacin is contained in tiny fat particles known as liposomes, which allows the medicine to remain in the lung for longer.

A main study in 336 patients showed that Arikayce liposomal is effective at clearing lung infections caused by MAC. After 6 months of treatment, 29% of patients on standard care who used Arikayce liposomal tested negative for the infection, compared with 9% of patients on standard care alone. In addition, 3 months after stopping treatment, 55% of patients whose infections cleared with Arikayce liposomal continued to test negative. No patient who received standard care tested negative 3 months after stopping treatment.

The most common side effects with Arikayce liposomal affect the lungs and airways: dysphonia (changes to the voice), cough, dyspnoea (difficulty breathing) and haemoptysis (coughing up blood) may affect more than 1 person in 10.

Other common side effects include pain in the mouth or throat, tiredness, diarrhoea, worsening of bronchiectasis (weakened, scarred airways and build-up of mucus) due to infection, nausea (feeling sick) and bronchospasm.

Arikayce liposomal must not be used in patients who are hypersensitive (allergic) to soya, to any aminoglycoside antibiotic or to any ingredient of this medicine. It must also not be used together with another aminoglycoside or in patients with severely impaired kidneys.

For the full list of side effects of Arikayce liposomal, see the package leaflet.

The main study showed that Arikayce liposomal can clear MAC lung infection in some patients. Although the effect of Arikayce liposomal is modest, the medicine could benefit patients who have few treatment options. In terms of its safety, Arikayce liposomal can cause significant side effects, particularly during the first months of treatment. The Agency therefore recommended restricting the medicine to patients with limited treatment options.

The Agency concluded that the benefits of Arikayce liposomal outweigh its risks and that it can be authorised in the EU.

The company will provide patients taking the medicine with an alert card to inform them of the risk of allergic alveolitis (inflammation in the lungs due to an allergy).

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Arikayce liposomal have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Arikayce liposomal are continuously monitored. Side effects reported with Arikayce liposomal are carefully evaluated and any necessary action taken to protect patients.

Arikayce liposomal received a marketing authorisation valid throughout the EU on 27 October 2020.

Arikayce liposomal : EPAR - Medicine overview

български (BG) (148.8 KB - PDF)
español (ES) (125.25 KB - PDF)
čeština (CS) (146.4 KB - PDF)
dansk (DA) (123.55 KB - PDF)
Deutsch (DE) (116.52 KB - PDF)
eesti keel (ET) (122.69 KB - PDF)
ελληνικά (EL) (158.28 KB - PDF)
français (FR) (126.21 KB - PDF)
hrvatski (HR) (146.72 KB - PDF)
italiano (IT) (123.65 KB - PDF)
latviešu valoda (LV) (163.5 KB - PDF)
lietuvių kalba (LT) (147.29 KB - PDF)
magyar (HU) (147.02 KB - PDF)
Malti (MT) (156.58 KB - PDF)
Nederlands (NL) (124.33 KB - PDF)
polski (PL) (148.58 KB - PDF)
português (PT) (125.36 KB - PDF)
română (RO) (154.49 KB - PDF)
slovenčina (SK) (147.59 KB - PDF)
slovenščina (SL) (144.83 KB - PDF)
Suomi (FI) (122.95 KB - PDF)
svenska (SV) (123.61 KB - PDF)

Arikayce liposomal : EPAR - Risk-management-plan summary

Product information

Arikayce liposomal : Product information

български (BG) (621.88 KB - PDF)
español (ES) (507.79 KB - PDF)
čeština (CS) (599.81 KB - PDF)
dansk (DA) (510.32 KB - PDF)
Deutsch (DE) (522.59 KB - PDF)
eesti keel (ET) (495.64 KB - PDF)
ελληνικά (EL) (728.93 KB - PDF)
français (FR) (533.97 KB - PDF)
hrvatski (HR) (576.67 KB - PDF)
íslenska (IS) (508.84 KB - PDF)
italiano (IT) (532.1 KB - PDF)
latviešu valoda (LV) (598.78 KB - PDF)
lietuvių kalba (LT) (580.79 KB - PDF)
magyar (HU) (611.06 KB - PDF)
Malti (MT) (603.69 KB - PDF)
Nederlands (NL) (504.17 KB - PDF)
norsk (NO) (508.03 KB - PDF)
polski (PL) (595.07 KB - PDF)
português (PT) (507.16 KB - PDF)
română (RO) (600.06 KB - PDF)
slovenčina (SK) (601.53 KB - PDF)
slovenščina (SL) (574.39 KB - PDF)
Suomi (FI) (499.75 KB - PDF)
svenska (SV) (493.07 KB - PDF)

Latest procedure affecting product information: PSUSA/00010882/202209

29/06/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Arikayce liposomal : EPAR - All authorised presentations

български (BG) (56.99 KB - PDF)
español (ES) (48.19 KB - PDF)
čeština (CS) (54.27 KB - PDF)
dansk (DA) (48.79 KB - PDF)
Deutsch (DE) (49.46 KB - PDF)
eesti keel (ET) (47.88 KB - PDF)
ελληνικά (EL) (59.65 KB - PDF)
français (FR) (57.28 KB - PDF)
hrvatski (HR) (66.19 KB - PDF)
íslenska (IS) (47.93 KB - PDF)
italiano (IT) (47.19 KB - PDF)
latviešu valoda (LV) (64.15 KB - PDF)
lietuvių kalba (LT) (66.63 KB - PDF)
magyar (HU) (57.66 KB - PDF)
Malti (MT) (68.09 KB - PDF)
Nederlands (NL) (46.59 KB - PDF)
norsk (NO) (48.66 KB - PDF)
polski (PL) (67.89 KB - PDF)
português (PT) (49.07 KB - PDF)
română (RO) (62.17 KB - PDF)
slovenčina (SK) (64.49 KB - PDF)
slovenščina (SL) (65.26 KB - PDF)
Suomi (FI) (46.74 KB - PDF)
svenska (SV) (47.5 KB - PDF)

Product details

Name of medicine
Arikayce liposomal
Active substance
Amikacin sulfate
International non-proprietary name (INN) or common name
amikacin
Therapeutic area (MeSH)
Respiratory Tract Infections
Anatomical therapeutic chemical (ATC) code
J01GB06

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.

Authorisation details

EMA product number
EMEA/H/C/005264

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
Insmed Netherlands B.V.

Stadsplateau 7
3521 AZ Utrecht
Netherlands

Opinion adopted
23/07/2020
Marketing authorisation issued
27/10/2020
Revision
2

Assessment history

Arikayce liposomal : Procedural steps taken and scientific information after authorisation

Arikayce liposomal-H-C-PSUSA-00010882-202209 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Arikayce liposomal : Orphan designation assessment report (initial authorisation)

Arikayce liposomal : EPAR - Public assessment report

CHMP summary of positive opinion for Arikayce liposomal

This page was last updated on

How useful do you find this page?